Empowered Patient Podcast Lab Data Integration Key to Optimizing GLP-1 Drug Utilization for Cardiometabolic Diseases with Dr. Julie Schulz Avalon Healthcare Solutions
Dr. Julie Schulz, VP of product at Avalon Healthcare Solutions, a company that helps health plans manage their laboratory spend and benefits by contracting with labs and analyzing lab data. Lab tests are important for identifying the right patients for GLP-1 drugs and assessing their cardiometabolic health. While GLP-1 drugs were initially developed for diabetes they have been found to have broader benefits in treating conditions like obesity, heart disease, and kidney disease. Avalon's real-time access to lab data can help health plans and providers better identify appropriate patients for GLP-1 drugs and address health equity and access issues.
Julie explains, "Labs are increasingly looking at biomarkers that provide an overall sense of patient health. Molecular diagnostics, including genetic testing, is on the upswing. Understanding the complexities of that testing and the clinical decisions that come from it is more and more important for health plan employers in the broader healthcare ecosystem."
"So GLP-1 drugs were initially indicated for diabetes and help patients who struggle to control their diabetes with other medications to help bring down their hemoglobin A1c. But we found they have a much broader effect on the entire cardio kidney metabolic syndrome. Increasingly, clinicians in the American Heart Association are recognizing that cardiorenal metabolic syndrome is a collection of related disorders that involve cardiovascular disease, diabetes, obesity, liver disease, and others as well. What's interesting about GLP-1s is they've been shown to have an impact on many of these systems."
"Now all of those labs can come together and can actually be used to calculate a score of a patient's tenure and 30-year risk of major adverse cardiac events. So, heart attack and stroke, but also heart failure. So, bringing all those things together will inform the patient's broader cardiometabolic health status and can also help start identifying patients who will benefit the most from these drugs."
#AvalonHCS #LaboratoryBenefitsManager #HealthPlans #HealthEquity #GLP1 #CardiometabolicDiseases #Obesity #KidneyDisease #HeartDisease